Marit A. C. Vermunt

Statistics

Publications

Citations

H-Index

Active since

2020

Affiliations

The Netherlands Cancer Institute(Current)

Utrecht University

Teva Pharmaceuticals (Netherlands)

University Medical Center Utrecht

Oncode Institute

Marit A. C. Vermunt is an author at The Netherlands Cancer Institute specializing in pharmacology, pharmacy, and genitourinary cancer pharmacotherapy.

ORCID

Publications per year

2020–2021

Publications

Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours

Marit A. C. Vermunt, Lisa T. van der Heijden, Jeroen J. M. A. Hendrikx et al. · Cancer Chemotherapy and Pharmacology · 2021 · 14 citations

Pharmacy, Pharmacokinetics, Pharmacology +12

<scp>ModraDoc006</scp>, an oral docetaxel formulation in combination with ritonavir (<scp>ModraDoc006</scp>/r), in metastatic castration‐resistant prostate cancer patients: A phase Ib study

Marit A. C. Vermunt, Debbie Robbrecht, Lot A. Devriese et al. · Cancer Reports · 2021 · 12 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +11

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors

Mats Någård, Mei-Lin Ah-See, Karen So et al. · Cancer Chemotherapy and Pharmacology · 2020 · 11 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A Phase 1 Dose‐Escalation Study of Low‐Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors

Vincent A. de Weger, Marit A. C. Vermunt, Frederik E. Stuurman et al. · Clinical Pharmacology in Drug Development · 2020 · 11 citations

Medicine, Oncology, Pharmacology +16

1–4 of 4